title: Regulation of formyl peptide receptor expression and its mRNA levels during differentiation of HL-60 cells.
abstract: When incubated with N6-2'-O-dibutyryladenosine 3',5'-cyclic monophosphate (dbcAMP), HL-60 cells expressed formyl peptide receptor (FPR) (as assessed by ligand binding) and FPR transcripts in a time- and concentration-dependent fashion. Experiments using dbcAMP analogs modified at either the C-6 or C-8 position indicated that the process was mediated by a protein kinase A type I, and protein kinase A type I activity was isolated from undifferentiated HL-60 cells by DEAE-Sephacel chromatography. Forskolin mimicked the effects of dbcAMP. Forskolin and dbcAMP-dependent expression of FPR and FPR transcript was inhibited by staurosporine. Retinoic acid (but not retinal or retinol) was capable of inhibiting dbcAMP-dependent expression of FPR mRNA half-life. Dexamethasone enhanced the effects of dbcAMP and blocked the inhibitory effect of retinoic acid on expression of FPR and FPR transcripts. Phorbol 12-myristate 13-acetate (PMA) alone (1.5-15 nM) failed to induce HL-60 to express FPR and FPR transcripts. Low concentrations (1.5 nM) of PMA enhanced the ability of dbcAMP to induce HL-60 cells to express FPR and FPR transcript, whereas high (15 nM) concentrations of PMA inhibited dbcAMP effects. These results indicate that expression of FPR and FPR transcripts by HL-60 cells can be up- and down-regulated by agents that induce HL-60 cells to differentiate and that a "cross-talk" effect exists between protein kinase A and protein kinase C that modulates FPR gene transcription (and receptor expression) by these cells.
authors.affiliation: Rosalind Russell Arthritis Research Laboratory, University of California, San Francisco.
authors.forename: H D
authors.initials: HD
authors.lastname: Perez
authors.forename: E
authors.initials: E
authors.lastname: Kelly
authors.forename: R
authors.initials: R
authors.lastname: Holmes
mesh_terms: D000470:Alkaloids / Q000494:pharmacology; D001665:Binding Sites; D003994:Bucladesine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D002454:Cell Differentiation; D002853:Chromatography, Liquid; D005576:Colforsin / Q000037:antagonists & inhibitors / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D004336:Drug Antagonism; D005786:Gene Expression Regulation; D006801:Humans; D011493:Protein Kinase C / Q000378:metabolism; D011494:Protein Kinases / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism*; D044042:Receptors, Formyl Peptide; D011971:Receptors, Immunologic / Q000187:drug effects / Q000235:genetics*; D019311:Staurosporine; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014158:Transcription, Genetic / Q000187:drug effects; D014212:Tretinoin / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D015854:Up-Regulation
chemical_list: D000470:Alkaloids; D012333:RNA, Messenger; D044042:Receptors, Formyl Peptide; D011971:Receptors, Immunologic; D005576:Colforsin; D014212:Tretinoin; D003994:Bucladesine; D003907:Dexamethasone; D011494:Protein Kinases; D011493:Protein Kinase C; D019311:Staurosporine; D013755:Tetradecanoylphorbol Acetate